Mechanism of Action: Cyclin-dependent Kinase 6 Inhibitors
✉ Email this page to a colleague
Drugs with Mechanism of Action: Cyclin-dependent Kinase 6 Inhibitors
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
G1 Therap | COSELA | trilaciclib dihydrochloride | POWDER;INTRAVENOUS | 214200-001 | Feb 12, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
G1 Therap | COSELA | trilaciclib dihydrochloride | POWDER;INTRAVENOUS | 214200-001 | Feb 12, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
G1 Therap | COSELA | trilaciclib dihydrochloride | POWDER;INTRAVENOUS | 214200-001 | Feb 12, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
G1 Therap | COSELA | trilaciclib dihydrochloride | POWDER;INTRAVENOUS | 214200-001 | Feb 12, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
G1 Therap | COSELA | trilaciclib dihydrochloride | POWDER;INTRAVENOUS | 214200-001 | Feb 12, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
G1 Therap | COSELA | trilaciclib dihydrochloride | POWDER;INTRAVENOUS | 214200-001 | Feb 12, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |